Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 All clinical trial and long-term stability data required for the preparation of the New Drug ...

Acquisition provides Virbac with a leading specialty product, in a growing segment, to improve the quality of life for senior cats.

The evoBrix® X modular Medicaid Enterprise System (MES) platform that enables states to deploy new systems with greater speed and efficiency while maintaining the governance and compliance standards ...

Six years later, an 80-year-old woman stepped into Dr. Steele’s clinic with anxiety, depression, high blood pressure, arthritis, and a fresh dementia diagnosis. Though he had never treated dementia, ...

[1] Humbert M, Letard S, Goubard A, et al. Identification of AB8939, a novel synthetic microtubule destabilizer and ALDH inhibitor that overcomes multidrug resistance in tumor cells as a drug ...

On November 25, 2025, Claret European Growth Capital Fund III SCSp converted its portion of the Tranche A convertible OCABSA resulting in the issuance of 392,695 ordinary shares of the Company.

Clinical Development Program Appropriate for Rolling BLA . Submission Expected by the End of 2025. CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Na ...

Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma; Five-year analysis of median p ...

Vivos management will discuss the strategic business model pivot and operational execution; the market opportunity and competitive environment; and Vivos’ growth and financial strategies. To register ...

The securities described above will be offered by Kyverna pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-286180) that was filed with the Securities and Exchange ...

Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to ...

The shares of Common Stock underlying the Tranche A Warrants have been registered by Fractyl under the Securities Act of 1933, as amended, and are covered by a registration statement filed with, and ...